Physician Scientist Training in Clinical Oncology

项目概要和摘要 宾夕法尼亚大学保罗·卡拉布雷西职业生涯的竞争性续约申请 K12临床肿瘤学发展奖成立于1997年，已获得22项资助。 年通过这次更新，我们寻求继续支持6 MD或MD/PhD的培训和指导 致力于以患者为导向的癌症研究的研究人员。我们的K12的使命是识别 培养下一代优秀的翻译和临床研究人员，他们专注于 人类恶性肿瘤的问题。该计划提供了关键的保护时间，指导，资源， 教育经验和实现这一目标所需的环境。我们的培训计划不是 独立实体。它得到了显著的物质和人力资源以及强大的机构的支持 宾夕法尼亚大学佩雷尔曼医学院和艾布拉姆森癌症中心的承诺 中心和沿着的儿童癌症研究中心在儿童医院， 费城典型的学员已完成临床肿瘤学培训（奖学金或住院医师），并进入 这个K12补助金作为讲师或初级助理教授。我们已经任命了54名学员（学者）， 从各种临床肿瘤学培训计划（即， 血液学/肿瘤学奖学金，儿科血液学/肿瘤学奖学金，妇科肿瘤学 研究金、放射肿瘤学住院医师）。K12执行委员会根据学员的 证明了对转化和临床研究的承诺和承诺。一旦注册，我们的学者 根据他们的具体研究兴趣和教育， 通过教学课程和研究研讨会。大多数学者被任命为2年。唯一性 这K12是，它促进了在一个非常明确的方式“bench-to-bedside”的发展，翻译 研究，以及临床流行病学和卫生服务研究。我们学者的进步是 通过为每个学者定制的个性化计划以及K12计划的 咨询委员会还审查总体方案优先事项。我们已经建立了高 我们的研究导师谁来自不同背景的标准和期望。该计划 通过癌症研究中的出版物、资金和独立职业来衡量成功。在过去的22年里 多年来，我们的学者87%已经继续追求全职学术生涯，其中绝大多数 由NIH或其他来源独立资助。我们未来五年的目标是： 为所有学者提供成功的临床或翻译所需的知识和工具 研究人员，包括生物统计学、流行病学、生物伦理学和临床试验设计方面的培训，以及2）建立 我们最近成功地吸引和培训了各种各样的妇女和男子参加这种培训， 程序.

Project Summary and Abstract This competitive renewal application for the University of Pennsylvania's Paul Calabresi Career Development Award for Clinical Oncology K12 was established in 1997 and has received funding for 22 years. With this renewal, we seek continued support for the training and mentorship for 6 MD or MD/PhD investigators with a commitment to patient-oriented cancer research. Our K12's mission is to identify and train the next generation of outstanding translational and clinical investigators who are focused on the problem of human malignancies. This program provides the critical protected time, mentorship, resources, educational experience, and environment necessary to achieve this goal. Our training program is not a stand-alone entity. It is bolstered by the remarkable physical and human resources and strong institutional commitments of the Perelman School of Medicine of the University of Pennsylvania and Abramson Cancer Center and along with the Center for Childhood Cancer Research at the Children's Hospital of Philadelphia. Typical trainees have completed clinical oncology training (fellowship or residency) and enter this K12 grant as instructors or junior assistant professors. We have appointed 54 trainees (Scholars) from a deep pool of applicants fed from the various clinical oncology training programs (i.e. hematology/oncology fellowship, pediatric hematology/oncology fellowship, gynecologic oncology fellowship, radiation oncology residency). The K12 Executive committee selects trainees based on their demonstrated commitment and promise for translational and clinical research. Once enrolled, our Scholars embark upon a tailored curriculum based on their specific research interests and education, supplemented by didactic coursework and research seminars. Most Scholars are appointed for 2 years. The uniqueness of this K12 is that it facilitates in a very explicit manner the “bench-to-bedside” development of translational research, as well as clinical epidemiology and health services research. Progress of our Scholars is closely monitored with an individualized plan that is customized for each Scholar and by the K12 program's Advisory Committee, which also reviews overall programmatic priorities. We have established high standards and expectations for our research mentors who come from diverse backgrounds.The program measures success by publications, funding, and independent careers in cancer research. Over the last 22 years, 87% of our Scholars have gone on to pursue full-time academic careers, the vast majority of these with independent funding from NIH or other sources. Our broad goals for the next 5 years are to: 1) To prepare all of Scholars with the knowledge and tools necessary to be successful clinical or translational researchers, including training in biostatistics, epidemiology, bioethics and clinical trial design and 2) build upon our recent successes in attracting and training a diverse group of women and men to this training program.